$6100 | Single User
$10500 | Site License
$17000 | Enterprise License

Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027
[Lowest Price Guaranteed: $6,100]

Published by Black Swan Analysis: 01 Feb 2017 | 81378 | In Stock
Related Topics: Constipation , Delivery , Gas , Pain

Introduction

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Irritable Bowel Syndrome in 12 Major Markets

Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group of symptoms but includes abdominal pain and disturbed defecation. IBS is divided into several subtypes including:

• Diarrhoea predominant (IBS-D)

• Constipation predominant (IBS-C)

• Alternating (IBS-A)

• Pain predominant.

These subtypes are identified by the dominant symptoms that the patient experiences.

This report provides the current prevalent population for Irritable Bowel Syndrome across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Irritable Bowel Syndrome have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Irritable Bowel Syndrome include:

• Abdominal pain

• Abdominal cramping

• Bloated/Gassy feeling

• Gas (Flatulence)

• Diarrhoea

• Constipation

• Mucus in stools

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Irritable Bowel Syndrome market to target the development of future products, pricing strategies and launch plans.

• Gain further insight into the prevalence of the subdivided types of Irritable Bowel Syndrome and identify patient segments with high potential.

• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

• Provide a level of understanding on the impact from specific co-morbid conditions on Irritable Bowel Syndrome prevalent population.

• Identify sub-populations within Irritable Bowel Syndrome which require treatment.

• Gain an understanding of the specific markets that have the largest number of Irritable Bowel Syndrome patients.

Table of Contents
for Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027

  • Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Irritable Bowel Syndrome in 12 Major Markets

    Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group of symptoms but includes abdominal pain and disturbed defecation. IBS is divided into several subtypes including:

    • Diarrhoea predominant (IBS-D)

    • Constipation predominant (IBS-C)

    • Alternating (IBS-A)

    • Pain predominant.

    These subtypes are identified by the dominant symptoms that the patient experiences.

    This report provides the current prevalent population for Irritable Bowel Syndrome across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

    Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Irritable Bowel Syndrome have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

    Main symptoms and co-morbidities for Irritable Bowel Syndrome include:

    • Abdominal pain

    • Abdominal cramping

    • Bloated/Gassy feeling

    • Gas (Flatulence)

    • Diarrhoea

    • Constipation

    • Mucus in stools

    This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

    Reason to buy

    • Able to quantify patient populations in global Irritable Bowel Syndrome market to target the development of future products, pricing strategies and launch plans.

    • Gain further insight into the prevalence of the subdivided types of Irritable Bowel Syndrome and identify patient segments with high potential.

    • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

    • Provide a level of understanding on the impact from specific co-morbid conditions on Irritable Bowel Syndrome prevalent population.

    • Identify sub-populations within Irritable Bowel Syndrome which require treatment.

    • Gain an understanding of the specific markets that have the largest number of Irritable Bowel Syndrome patients.

List Of Tables
in Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Irritable Bowel Syndrome in 12 Major Markets

Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group of symptoms but includes abdominal pain and disturbed defecation. IBS is divided into several subtypes including:

• Diarrhoea predominant (IBS-D)

• Constipation predominant (IBS-C)

• Alternating (IBS-A)

• Pain predominant.

These subtypes are identified by the dominant symptoms that the patient experiences.

This report provides the current prevalent population for Irritable Bowel Syndrome across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Irritable Bowel Syndrome have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Irritable Bowel Syndrome include:

• Abdominal pain

• Abdominal cramping

• Bloated/Gassy feeling

• Gas (Flatulence)

• Diarrhoea

• Constipation

• Mucus in stools

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Irritable Bowel Syndrome market to target the development of future products, pricing strategies and launch plans.

• Gain further insight into the prevalence of the subdivided types of Irritable Bowel Syndrome and identify patient segments with high potential.

• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

• Provide a level of understanding on the impact from specific co-morbid conditions on Irritable Bowel Syndrome prevalent population.

• Identify sub-populations within Irritable Bowel Syndrome which require treatment.

• Gain an understanding of the specific markets that have the largest number of Irritable Bowel Syndrome patients.

List Of Figures, Charts and Diagrams
in Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027

See List of Tables for the Figures

Additional Details

Publisher

Black Swan Analysis

Publisher Information

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we’ve seen what works and what doesn’t and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today’s complex healthcare marketplace.



The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.



We have the capability to provide an immediate and ‘hands-on’ approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.



The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.



Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Reference

81378 | IBSN0010217

Number of Pages

48

Report Format

PDF

Black Swan Analysis Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Irritable Bowel Syndrome - Epidemiology Forecast To 2023
DelveInsight “Irritable Bowel Syndrome - Epidemiology Forecast To 2023” provides an overview of the ...
31 May 2017 by Delve Insight USD $2,750 More Info
Irritable Bowel Syndrome-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent ...
30 May 2017 by Delve Insight USD $1,250 More Info
Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Irritable Bowel Syndrome -...
30 May 2017 by Delve Insight USD $4,950 More Info
Irritable Bowel Syndrome - Pipeline Review, H1 2017
Irritable Bowel Syndrome - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceuti...
23 May 2017 by Global Markets Direct USD $2,000 More Info
Global Irritable Bowel Syndrome Partnering 2010-2017
The Global Irritable Bowel Syndrome Partnering Terms and Agreements since 2010 report provides under...
01 Apr 2017 by Current Partnering USD $1,495 More Info
Global Irritable Bowel Syndrome Partnering 2010-2017
The Global Irritable Bowel Syndrome Partnering Terms and Agreements since 2010 report provides under...
01 Feb 2017 by Current Partnering USD $1,495 More Info
Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2016
Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
30 Nov 2016 by Global Data USD $2,500 More Info
Global Irritable Bowel Syndrome Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Irritable Bowel Syndrome Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2015
Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial r...
16 Dec 2015 by Global Data USD $2,500 More Info

This report is published by Black Swan Analysis

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we’ve seen what works and what doesn’t and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today’s complex healthcare marketplace.

The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.

We have the capability to provide an immediate and ‘hands-on’ approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.

The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.

Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Download Free Report Summary PDF

Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...